TITAN PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.01 USD | 0.00% |
|
-3.41% | -15.03% |
| Apr. 01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
Financials (USD)
| Sales 2022 | 557K | Sales 2023 | 184K | Capitalization | 6.21M |
|---|---|---|---|---|---|
| Net income 2022 | -10M | Net income 2023 | -5M | EV / Sales 2022 | 15.6 x |
| Net cash position 2022 | 2.75M | Net cash position 2023 | 6.2M | EV / Sales 2023 | 0.11 x |
| P/E ratio 2022 |
-1.03
x | P/E ratio 2023 |
-1.11
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.53% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -3.41% | ||
| Current month | -2.09% | ||
| 1 month | +11.45% | ||
| 3 months | +20.65% | ||
| 6 months | +3.09% | ||
| Current year | -15.03% |
1 week
7.01
7.32
1 month
6.309.07
Current year
5.259.35
1 year
5.0016.60
3 years
5.0062.00
5 years
5.001 308.00
10 years
5.0036 000.05
| Members of the board | Title | Age | Since |
|---|---|---|---|
Avraham Ben-Tzvi
BRD | Director/Board Member | 53 | 22-08-14 |
Gim Shen Seow
CEO | Chief Executive Officer | 42 | 23-10-11 |
Brynner Chiam
BRD | Director/Board Member | - | 23-10-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 7.01 | 0.00% | 1,329 |
| 24-04-22 | 7.01 | -4.23% | 604 |
| 24-04-19 | 7.32 | +3.09% | 2,979 |
| 24-04-18 | 7.1 | 0.00% | 5,243 |
| 24-04-17 | 7.1 | -2.17% | 2,565 |
Delayed Quote Nasdaq, April 23, 2024 at 04:30 pm EDT
More quotes
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Sector
Pharmaceuticals
Calendar
2024-11-10
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.03% | 6.41M | |
| +27.92% | 672B | |
| +27.13% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.38% | 217B | |
| +5.66% | 199B | |
| -8.30% | 204B | |
| -8.58% | 149B |
- Stock Market
- Equities
- TTNP Stock
